Siegfried successfully completes acquisition of an early-phase CDMO in
Wisconsin (US)

   Siegfried AG / Key word(s): Acquisition
   Siegfried successfully completes acquisition of an early-phase
   CDMO in Wisconsin (US)
   02.07.2024 / 06:30 CET/CEST
     ____________________________________________________________

   
   Siegfried (SIX: SFZN) has completed the acquisition of an
   early-phase CDMO site in Grafton, Wisconsin (US) from Curia
   Global, strengthening Siegfried's customer offering for Drug
   Substances in terms of capabilities and geography.

   The acquisition was announced on June 12, 2024, and was completed
   on July 1, 2024 with effect as of the same day.

   Reto Suter, CEO ad interim and CFO of Siegfried: "We warmly
   welcome our new Siegfried colleagues to our network. This
   acquisition significantly enhances our early-stage development
   services for Drug Substances, strengthens our geographical
   coverage and will generate attractive opportunities. It will
   further accelerate our growth story."

   The acquisition reinforces Siegfried's position in the United
   States, the world's largest pharmaceutical market. Siegfried
   intends to develop the site into its Siegfried Acceleration Hub
   for early-phase CDMO services to provide comprehensive support to
   customers in the pre-clinical and clinical development and
   manufacturing of Drug Substances. This further expands
   Siegfried's offering, particularly for small and medium-sized
   pharmaceutical companies. The focus on early-phase CDMO services
   will fuel Siegfried's Drug Substance pipeline by capturing
   additional attractive opportunities in their early stage,
   creating significant growth opportunities in the future.

   As part of the acquisition, all projects at the Grafton site have
   been transferred to Siegfried and the Siegfried Acceleration Hub
   will continue to fulfill all commitments to its existing
   customers.
   Contact

   Financial Analysts:     Media:
   Dr. Reto Suter          Peter Stierli
   Chief Financial Officer Head Corporate Communications
   reto.suter@siegfried.ch peter.stierli@siegfried.ch
   Tel. +41 62 746 11 35   Tel. +41 62 746 15 51

Siegfried Holding AG

Untere Bruehlstrasse 4

CH-4800 Zofingen

   About Siegfried
   The Siegfried Group is a global life sciences company with sites
   in Switzerland, Germany, Spain, France, Malta, the USA and China.
   In 2023, the company achieved sales of CHF 1.272 billion and
   employed on 31.12.2023 more than 3700 people at twelve sites on
   three continents. Siegfried Holding AG is publicly listed on the
   SIX Swiss Exchange (SIX: SFZN).
   Siegfried is active in manufacturing pharmaceutical APIs (and
   their intermediates) as well as drug products (tablets, capsules,
   sterile vials, ampoules, cartridges and ointments) for the
   pharmaceutical industry and provides development services.
   Cautionary Statements Regarding Forward-Looking Statements
   This media release includes statements concerning the future.
   They are based on assumptions and expectations that may prove to
   be wrong. They should be considered with due caution as, by
   definition, they contain known and unknown risks, insecurities
   and other factors which could result in a difference in the
   actual results, financial situation, developments or the success
   of Siegfried Holding AG or Siegfried Group from the explicit or
   implicit assumptions made in these statements.

expect more

   Siegfried AG
   Untere Brühlstrasse 4
   4800 Zofingen, Switzerland
   +41 62 746 11 11
   info@siegfried.ch
   www.siegfried.ch

____________________________________________________________

   End of Media Release
     ____________________________________________________________

   Language:    English
   Company:     Siegfried AG
                Untere Brühlstrasse 4
                4800 Zofingen
                Switzerland
   Phone:       +41 62 746 11 11
   E-mail:      info@siegfried.ch
   Internet:    https://www.siegfried.ch
   ISIN:        CH0014284498
   Listed:      SIX Swiss Exchange
   EQS News ID: 1936867

   End of News EQS News Service
     ____________________________________________________________

1936867 02.07.2024 CET/CEST